Company intelligence / Profile preview

Henning Berlin

Berlin, Berlin, Germany

Ownership: Private
Development stage: Other

Overview

Henning Berlin developed procalcitonin as a biomarker for early sepsis detection, which became the standard for clinical use; also known for manufacturing pharmaceuticals such as levothyroxine sodium. After a management buy-out in 1994, the company contributed key developments in diagnostic biomarkers but does not exist independently anymore.

Therapeutic areas: Infectious DiseasesEndocrinology
Modalities: Small moleculeDiagnostic biomarker
Industry: Biotech

Beyond the preview

Go deeper on Henning Berlin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Henning Berlin.

Explore the full profile